Dae‐Kee Kim

2.1k total citations
68 papers, 1.8k citations indexed

About

Dae‐Kee Kim is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Dae‐Kee Kim has authored 68 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 27 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Dae‐Kee Kim's work include TGF-β signaling in diseases (27 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Histone Deacetylase Inhibitors Research (8 papers). Dae‐Kee Kim is often cited by papers focused on TGF-β signaling in diseases (27 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Histone Deacetylase Inhibitors Research (8 papers). Dae‐Kee Kim collaborates with scholars based in South Korea, United States and Japan. Dae‐Kee Kim's co-authors include Yhun Yhong Sheen, Hyun‐Ju Park, Cheng Hua Jin, Jeong‐Seok Nam, Chul‐Yong Park, Maddeboina Krishnaiah, Namkyu Lee, Vura Bala Subrahmanyam, D. Sreenu and So-Yeon Park and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Cancer Research.

In The Last Decade

Dae‐Kee Kim

67 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dae‐Kee Kim South Korea 27 982 640 374 212 160 68 1.8k
Paul Peixoto France 24 1.2k 1.2× 443 0.7× 269 0.7× 318 1.5× 194 1.2× 48 1.8k
Sally Przybranowski United States 16 1.8k 1.8× 757 1.2× 316 0.8× 187 0.9× 278 1.7× 24 2.5k
Tingting Zhao China 25 759 0.8× 314 0.5× 271 0.7× 288 1.4× 83 0.5× 74 1.5k
Debra A. Tonetti United States 26 935 1.0× 662 1.0× 106 0.3× 245 1.2× 178 1.1× 57 1.7k
Xiaobing Deng United States 24 1.2k 1.2× 436 0.7× 138 0.4× 300 1.4× 195 1.2× 39 1.8k
Uma Yasothan United States 22 608 0.6× 433 0.7× 236 0.6× 68 0.3× 287 1.8× 30 1.4k
Alain De Pover Switzerland 16 1.2k 1.3× 341 0.5× 139 0.4× 142 0.7× 86 0.5× 25 1.6k
Toshitaka Manda Japan 21 1.0k 1.0× 247 0.4× 252 0.7× 183 0.9× 168 1.1× 53 1.5k
D. Lynn Kirkpatrick United States 18 1.4k 1.4× 282 0.4× 224 0.6× 436 2.1× 126 0.8× 34 1.8k
Edward K. Han United States 26 1.2k 1.2× 764 1.2× 182 0.5× 233 1.1× 81 0.5× 32 1.9k

Countries citing papers authored by Dae‐Kee Kim

Since Specialization
Citations

This map shows the geographic impact of Dae‐Kee Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dae‐Kee Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dae‐Kee Kim more than expected).

Fields of papers citing papers by Dae‐Kee Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dae‐Kee Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dae‐Kee Kim. The network helps show where Dae‐Kee Kim may publish in the future.

Co-authorship network of co-authors of Dae‐Kee Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Dae‐Kee Kim. A scholar is included among the top collaborators of Dae‐Kee Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dae‐Kee Kim. Dae‐Kee Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Eun Soo, et al.. (2023). Beneficial Effects of a Curcumin Derivative and Transforming Growth Factor-β Receptor I Inhibitor Combination on Nonalcoholic Steatohepatitis. Diabetes & Metabolism Journal. 47(4). 500–513. 7 indexed citations
2.
Zeng, Chu Hui, et al.. (2022). Different routes of administering EW-7197 versus EW-7197⋅HBr for preventing peritoneal adhesion in a rat model. Surgery. 173(4). 1008–1014. 3 indexed citations
3.
Kim, Min‐Jin, Sang-A Park, So-Yeon Park, et al.. (2016). TGF-β Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1α-Induced Epithelial Mesenchymal Transition. Cellular Physiology and Biochemistry. 38(2). 571–588. 47 indexed citations
4.
Son, Ji Yeon, So-Yeon Park, Sang-A Park, et al.. (2014). EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis. Molecular Cancer Therapeutics. 13(7). 1704–1716. 91 indexed citations
5.
Jin, Cheng Hua, Maddeboina Krishnaiah, D. Sreenu, et al.. (2014). 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase. Bioorganic & Medicinal Chemistry. 22(9). 2724–2732. 32 indexed citations
6.
Jung, Su Myung, Seok Hee Park, Mitsuyasu Kato, et al.. (2014). Activin receptor‐like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes. EMBO Molecular Medicine. 6(5). 703–703. 52 indexed citations
7.
Jung, Su Myung, Seok Hee Park, Mitsuyasu Kato, et al.. (2013). Activin receptor‐like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes. EMBO Molecular Medicine. 5(11). 1720–1739. 58 indexed citations
8.
Kim, Dae‐Kee, et al.. (2012). Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer. Biomolecules & Therapeutics. 20(3). 313–319. 5 indexed citations
9.
Krishnaiah, Maddeboina, Cheng Hua Jin, D. Sreenu, et al.. (2012). Synthesis and biological evaluation of 2-benzylamino-4(5)-(6-methylpyridin-2-yl)-5(4)-([1,2,4]triazolo[1,5-a]-pyridin-6-yl)thiazoles as transforming growth factor-β type 1 receptor kinase inhibitors. European Journal of Medicinal Chemistry. 57. 74–84. 23 indexed citations
10.
Jin, Cheng Hua, Maddeboina Krishnaiah, D. Sreenu, et al.. (2011). Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(20). 6049–6053. 36 indexed citations
11.
Park, Chul‐Yong, et al.. (2011). EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. European Journal of Cancer. 47(17). 2642–2653. 37 indexed citations
12.
13.
Luo, Jian, Peggy P. Ho, Marion S. Buckwalter, et al.. (2007). Glia-dependent TGF-β signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. Journal of Clinical Investigation. 117(11). 3306–3315. 101 indexed citations
14.
Park, Jung‐Hyun, Hyun-Soon Jong, Sang Gyun Kim, et al.. (2007). Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. Journal of Molecular Medicine. 86(1). 117–128. 45 indexed citations
15.
Jeong, Jae Min, Jaetae Lee, Chang H. Paik, et al.. (2004). Site-specific99mTc-labeling of antibody using dihydrazinophthalazine (DHZ) conjugation to Fc region of heavy chain. Archives of Pharmacal Research. 27(9). 961–967. 10 indexed citations
16.
Moon, Hyung Ryong, Prashantha Gunaga, Hea Ok Kim, et al.. (2004). Synthesis of d- and l-apio nucleoside analogues with 2′-hydroxyl group as potential anti-HIV agents. Bioorganic & Medicinal Chemistry. 12(5). 1101–1109. 9 indexed citations
17.
Kim, Dae‐Kee, et al.. (2004). Design, synthesis, and biological evaluation of novel 2-pyridinyl-[1,2,4]triazoles as inhibitors of transforming growth factor β1 type 1 receptor. Bioorganic & Medicinal Chemistry. 12(9). 2013–2020. 22 indexed citations
18.
Kim, Dae‐Kee, et al.. (2004). Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor. Bioorganic & Medicinal Chemistry Letters. 14(10). 2401–2405. 80 indexed citations
19.
Kim, Dae‐Kee, et al.. (2000). cis-[(4R,5R)-4,5-Bis(aminomethyl)-2,2-dimethyl-1,3-dioxolane-N,N′](malonato-O,O′)platinum(II), an anticancer agent. Acta Crystallographica Section C Crystal Structure Communications. 56(6). 653–654. 1 indexed citations
20.
Jang, In‐Jin, Kyung‐Sang Yu, Ji‐Hong Shon, et al.. (2000). Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Potassium Channel Opener, SKP‐450, in Healthy Volunteers. The Journal of Clinical Pharmacology. 40(7). 752–761. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Peixoto Breakdown of academic impact, for papers by Sally Przybranowski Breakdown of academic impact, for papers by Tingting Zhao Breakdown of academic impact, for papers by Debra A. Tonetti Breakdown of academic impact, for papers by Xiaobing Deng Breakdown of academic impact, for papers by Uma Yasothan Breakdown of academic impact, for papers by Alain De Pover Breakdown of academic impact, for papers by Toshitaka Manda Breakdown of academic impact, for papers by D. Lynn Kirkpatrick Breakdown of academic impact, for papers by Edward K. Han
Rankless by CCL
2026